VP, Enzyme Therapies Business Unit, Clinical Science

The Vice President, Enzyme Therapies, Clinical Development is the head of R&D for BioMarin’s Enzyme Therapies Business Unit (BU), responsible for overall strategic direction, development, and lifecycle management of BU pipeline assets.

• Strategic leadership: Develop and execute the Enzyme Therapies BU pipeline strategy, including lifecycle management of marketed products and development of future drug assets.
• Pipeline optimization: Select and prioritize assets, balancing risk, investment, and return; achieve or exceed Long Range Plan (LRP) revenue and growth goals.
• Cross-functional team leadership: Build and lead a high‑performing cross‑functional development strategy team (including clinicians and asset team leaders).
• Enterprise & stakeholder alignment: Partner with clinical, regulatory, commercial, medical, portfolio strategy, and business development to align prioritization, planning, and execution with near-, mid-...